Photo credit: Adrian Black/Creative Commons
Sanofi will collaborate with Google to develop new tools to monitor diabetes patients and improve outcomes.
The announcement on Tuesday adds to the growing number of partnerships between pharma companies that have turned to Google as a way to expand their services and better understand the diseases they treat.
The Joslin Diabetes Center, a well-known research center and clinic in Boston, is also a partner in the collaboration. Terms of the deal were not disclosed.
Sanofi and Google said they will study how to improve care in patients with type-1 and type-2 diabetes, with a focus on health “indicators,” which include measuring blood-glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.
Sanofi’s diabetes product portfolio, which includes Lantus and Apidra, brought in $2.2 billion in sales in the second quarter of 2015.
“Technology, sensors, analytics, and digital solutions will revolutionize how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care,” John Brooks III, president and CEO of the Joslin Diabetes Center, said in a release.
The search giant has also partnered with device-maker Dexcom. In August the companies said they planned to develop a disposable device that is applied to the skin and can send blood-sugar measurements to a smartphone. Novartis, too, has licensed Google’s “smart lens” technology to its eye-care arm Alcon to produce a contact lens that measures the blood-glucose levels of tears, while Biogen said it will collaborate with Google to use sensors to explore why multiple sclerosis progresses differently in patients.